INVESTIGATOR-SPONSORED RESEARCH AGREEMENT
(Pre-clinical; ex-US Grant Recipient; ex-US Study; Single-site ex-US)

This Investigator-Sponsored Research ("**ISR**") Agreement (the "**Agreement**") by and between

DECRETO DEL DIRETTORE GENERALE - N. 4305 del 28/10/2026 - Allegato Utente 1 (A01)

Pfizer International LLC with an address of **66 Hudson Boulevard East, New York, NY 10001, USA** ("**Pfizer**") and

Fondazione IRCCS Policlinico Ca' Granda Ospedale Maggiore with an address of **Via Francesco Sforza 35, Milan 20122, Italy** ("**Institution**"),

is effective as of the date last signed ("**Effective Date**").

Dr. Francesca Lazzaroni, an employee or a contractor of Institution ("**Principal Investigator**"), designed and intends to conduct a pre-clinical study entitled "**Ultra-sensitive Mapping of BCMA Evolutionary Trajectories to Decode Resistance in Multiple Myeloma via Super RCA**" Pfizer Tracking Number **104003351** (the "**Study**"). The Study involves the Pfizer asset Elranatamab. Pfizer wishes to provide certain support for the Study.

The parties agree as follows:

1. STUDY CONDUCT

1.1. Protocol. Institution will conduct the Study in accordance with a protocol developed by Principal Investigator (the "**Protocol**"). If Principal Investigator modifies the Protocol in a material way (e.g., changes to timelines, dosing), Institution will promptly inform Pfizer in writing.

1.2. Sponsorship. Institution will not, and will ensure that its employees, staff, agents, consultants, subcontractors and Principal Investigator (collectively, "**Staff**") will not, represent to any third party that Pfizer is a regulatory sponsor of the Study. Institution may delegate duties and responsibilities to Staff as permitted by Applicable Requirements.

1.3. Regulatory Obligations. Institution is solely responsible for any regulatory obligations and authorizations associated with the Study.

1.4. Compliance with Applicable Requirements. Institution will conduct the Study and undertake Study-related activities in accordance with Applicable Requirements and ensure compliance with Applicable Requirements by its Staff involved in the Study. "**Applicable Requirements**" means: (i) the terms of this Agreement; (ii) the Protocol; (iii) the terms of any institutional review board ("**IRB**") or independent ethics committee ("**IEC**") and regulatory authority approvals, if required for this type of Study; (iv) all applicable laws, rules, regulations guidelines or requirements of any federal, national, state or local court, agency, authority, department, regulatory body or other governmental instrument that may be in effect during the performance of the Study in any region or

regulatory jurisdiction in which the Study is conducted ("**Applicable Law**"); (v) all applicable good practice quality guidelines and regulations encompassing internationally recognized standards such as Good Laboratory Practice; and (vi) applicable guidelines of the International Council on Harmonisation.

1.5. IRB/IEC Approval. If required, Institution will ensure that the Study is approved by and subject to continuing oversight by an IRB/IEC. If IRB/IEC approval is required, Institution will provide Pfizer with documentation of the initial IRB/IEC approval, any renewals, and any IRB/IEC-approved amendments to the Protocol. Institution will notify Pfizer promptly of any withdrawal or suspension of IRB/IEC approval.

1.6. Use of Laboratory Animals. If the Study involves laboratory animals, Institution will ensure that: (i) the Study is approved by and subject to continuing oversight by a relevant institutional animal care and use committee; and (ii) any animals used in the Study are handled, housed and, as appropriate, disposed of in accordance with recognized guidelines for research use of animals, such as those issued by the Council for International Organizations of Medical Sciences or the National Institutes of Health.

1.7. Biological Samples. If the Study involves the use of human biological samples (e.g., cells, cell cultures, blood, urine, tissue, saliva) ("**Biological Samples**") provided by Institution, the following will apply:

1.7.1. Consent. Institution will: (i) obtain informed consent from individuals from whom Biological Samples were obtained ("**Sample Donors**") in accordance with Applicable Law; or (ii) ensure that an informed consent that covers the research to be conducted has been obtained; or (iii) obtain a waiver of informed consent from the appropriate IRB/IEC. Pfizer will not participate in the development of, or to review or comment on, an informed consent document or waiver request.

1.7.2. Ownership and Disposition. Pfizer makes no claim of ownership to Biological Samples provided for the Study by Institution. Institution is responsible for appropriate disposition of Biological Samples at the end of the Study.

1.8. Safety Reporting. Institution is solely responsible for any safety reporting obligations associated with the Study required by Applicable Law. Within 24 hours after discovery, Principal Investigator will report to Pfizer any adverse experience associated with the use of the Pfizer Product that is both serious and unexpected, as well as any finding that suggests a significant risk for human subjects. The Principal Investigator will submit such a report to Pfizer by e-mail to CTPGrants@pfizer.com. Examples of findings to be reported to Pfizer include:

- Positive findings in mutagenicity assays, teratogenicity or in carcinogenicity studies
- Life-threatening previously unknown toxicity
- A substantial and unexpected increase in severity of a known toxicity
- Test article-related death at doses of the Pfizer Product lower than those at which death occurred in previous studies

- In vitro findings that suggest a significant risk in humans exposed to the Pfizer Product.

1.9. Duration. "**Study Completion**" means the completion of all Study activities and completion of all Protocol requirements. Principal Investigator expects to achieve Study Completion by **31.07.2028.**

1.10. Status Updates. Institution will provide Pfizer with an online update of Study progress on a quarterly basis through the designated grant management system. Each update will include any information reasonably requested by Pfizer. If applicable, Institution will also provide Pfizer with a brief online update of Study subject enrollment on a monthly basis. Failure to submit required updates may result in termination of the grant. All required progress and final reports must be submitted directly through the grant management system and will not be accepted via email or other offline methods.

1.11. Required Disclosure of Investigator's Brochure. Notwithstanding any other obligations of confidentiality of Institution under this Agreement, if Institution is required under Applicable Requirements to publicly disclose an Investigator's Brochure ("**IB**"), <Institution> will only disclose an approved, redacted version of the IB. <Institution> will request a redacted version of the IB from Pfizer if one is not provided. <Institution> will promptly notify Pfizer of any unauthorized disclosure or publication of an unredacted IB.

2. INVESTIGATOR-SPONSORED RESEARCH SUPPORT

2.1. ISR Support.

Pfizer will provide funding in support of the Study up to a maximum amount of **81,000.00 euros** in accordance with the schedule set forth in Attachment A ("**ISR Support**").

2.2. Basis of Support. The ISR Support is not conditioned on: (i) any pre-existing or future business relationship between Pfizer and either Principal Investigator or Institution; or (ii) any business or other decisions Principal Investigator or Institution has made, or may make, relating to Pfizer or Pfizer products. Nothing in this Agreement will be construed in any manner as an obligation or inducement for Institution or Principal Investigator to purchase, order, prescribe or recommend any product of Pfizer or any Pfizer affiliate

2.3. Submission of Required Documents. Pfizer will not provide any component of the ISR Support until it has received documentation of IRB/IEC approval, exemption or waiver (if required), and the Protocol.

2.4. Use of ISR Support. Institution will use the ISR Support solely for purposes of the Study. If a third party is providing funding for the Study, Institution will use the ISR Support only for Study activities that are not covered by such third party funding. No portion of the ISR Support may be used to purchase capital equipment such as computers, iPhones,

tablets, appliances, machinery, camera equipment, sensors, facilities construction, etc.

2.5. No Charge to Third Parties. Institution will ensure that no governmental entity or third party payor is charged for any Study-related activities carried out by Institution using the ISR Support.

2.6. Budget. Institution represents that the Institution-provided Study budget upon which the ISR Support is based reflects an informed, reasonable, estimate of funds required to complete and report the Study, including, if applicable, expenses relating to the publication of Study Results.

2.7. Disclosure by Pfizer. In the interest of transparency relating to its financial relationships with investigators and study sites or to ensure compliance with Applicable Law, industry codes and Pfizer policies, Pfizer may report or otherwise publicly disclose payments or other transfers of value to certain health care providers, teaching hospitals and other health care organizations, including the ISR Support. These laws, policies, and codes, and their implementing regulations, are collectively "**Transparency Obligations**." Pfizer may disclose in any lawful manner any information necessary for Pfizer to meet its Transparency Obligations.

2.7.1. *Disclosure Content*. Pfizer may identify Institution and Principal Investigator and will differentiate clearly between payments or other transfers of value made to institutions and those made to individuals. Disclosures may include identifying information such as name, business address, specialty, and license numbers.

2.7.2. *Agreement and Cooperation*. Institution accepts and agrees to these disclosures on behalf of itself and its Principal Investigator. Institution will reasonably cooperate with Pfizer in Pfizer's collection and disclosure of information necessary to fulfill its Transparency Obligations.

3. PFIZER PRODUCT

Pfizer will not provide the Pfizer product Elranatamab (the "**Pfizer Product**") for the Study.

4. CONFIDENTIALITY

4.1. Pfizer Confidential Information. "**Pfizer Confidential Information**" means all information that is disclosed hereunder by or on behalf of Pfizer or any Pfizer affiliate to Institution including information relating to Pfizer's or any member of Pfizer's group's business, its products (including the Pfizer Product), operations, processes, plans or intentions, software, pricing, developments, know-how, design rights, market opportunities, personnel, suppliers and customers, and all information derived from any of the above (other than Study Data and Study Results).

4.2. Exclusions. Pfizer Confidential Information does not include information that:

4.2.1. is known or open to the public or otherwise in the public domain at the time of disclosure;

4.2.2. becomes known or open to the public or part of the public domain by any means other than breach of this Agreement by Institution;

4.2.3. is already known to Institution at the time of disclosure and is free of any obligations of confidentiality;

4.2.4. is obtained by Institution, free of any obligations of confidentiality, from a third party that has a lawful right to disclose it; or

4.2.5. is independently developed, as documented by written records, by individuals at Institution without the use of, reference to, aid from, or reliance on, the Pfizer Confidential Information.

4.3. Obligations of Confidentiality. Unless Pfizer provides prior written consent or as otherwise expressly permitted herein, Institution may not use Pfizer Confidential Information for any purpose except to conduct the Study and will not disclose Pfizer Confidential Information to any third party except as otherwise authorized in this Agreement. Institution will notify Pfizer immediately if it becomes aware of any disclosure in breach of the obligations in this Section 4.

4.4. Disclosure Required by Law. If disclosure of Pfizer Confidential Information other than as expressly permitted under this Agreement is required by law, that disclosure does not constitute a breach of this Agreement so long as Institution:

4.4.1. to the extent legally permitted, notifies Pfizer in writing as far as possible in advance of the disclosure so as to allow Pfizer to take legal action to protect its Pfizer Confidential Information;

4.4.2. discloses only that Pfizer Confidential Information required to comply with the legal requirement; and

4.4.3. continues to maintain the confidentiality of this Pfizer Confidential Information with respect to all other third parties.

4.5. Institution Information. Any information or materials provided to Pfizer by Institution related to the Study or the ISR Support are non-confidential and will not contain any markings claiming confidentiality. Institution acknowledges that Pfizer will not treat such information or materials as confidential or assume any obligation to keep them confidential. Institution's rights with respect to such information or materials will be only those obtained under patent laws and/or under a separate written agreement between Institution and Pfizer. Institution agrees that it has not, and will not, submit, any confidential information to Pfizer in connection with the Study or the ISR Support. Institution acknowledges that Pfizer may conduct ongoing or future research substantially

similar or identical to the Study. In consideration of the ISR Support, to the fullest extent allowed, Institution releases Pfizer from any and all liability for use of all or any portion of information or materials provided by Institution in connection with the Study and the ISR Support, other than for infringement of any patent.

"**Institution Information**" means: (i) the Protocol; (ii) the Study Report; (iii) a Publication until it is published; and (iv) information about a Product-Related Invention for which Pfizer has received a notice of invention. Pfizer will use Institution Information only for internal review and will disclose it only as required by Applicable Law. Pfizer's obligations with respect to Product-Related Inventions in Section 4.5(iv) will survive until the earliest of: (a) filing of a patent application on the respective Product-Related Invention (b) the Product-Related Invention owner(s) having notified Pfizer that they will not pursue a patent; or (c) one year after disclosure to Pfizer.

4.6. Survival of Obligations. This Section 4 will survive for five years after termination of this Agreement.

5. STUDY DATA, STUDY RESULTS AND STUDY REPORT

5.1. Definitions.

5.1.1. "**Study Data**" means raw, non-aggregated data collected during the course of the Study as required by the Protocol.

5.1.2. "**Study Results**" refers to aggregated or summarized Study Data and conclusions about the Study, as would be included in a study report or publication.

5.1.3. "**Study Report**" means a written report of the Study Results.

5.2. Use of Study Results and Study Data. Institution owns and is free to use the Study Results for any lawful purpose including publication in accordance with this Agreement. Institution owns and is free to use the Study Data for its own research and educational purposes. In consideration of the ISR Support provided by Pfizer's independent research grant program, Institution will not use, or permit any third parties to use, the Study Data for commercial benefit. For clarity, and subject to conformity with Applicable Requirements and any relevant underlying informed consent document(s), Institution may share Study Data with any third party supporting the Study that is identified in the grant proposal approved by Pfizer, provided, however, that Institution enters into a written agreement with such third party and such agreement contains limitations on use of Study Data and obligations of confidentiality to Institution at least as restrictive as those contained in this Agreement.

5.3. Study Report. Within six months of the earlier of Study Completion or termination of this Agreement Institution will provide Pfizer with a Study Report which may take the form of a manuscript. If the Agreement is terminated early, the Study Report should include, at minimum, the Study Results through the date of termination.

6. PUBLICATIONS. Pfizer encourages Institution to publish the Study Results, whether or not they are favorable to Pfizer or any Pfizer product. Institution will submit any proposed journal article, abstract, presentation or other type of public disclosure that reports any Study Results ("**Publication**") to Pfizer prior to submission or disclosure. Pfizer will review for Pfizer Confidential Information and provide comments within 30 days (the "**Review Period**"). The Review Period will be extended for an additional 30 days if Pfizer requests time to prepare a patent filing relating to any Invention to which it has rights. If Pfizer requests deletion of any Pfizer Confidential Information, Institution will comply with Pfizer's requests. Institution will comply with standard academic practices regarding authorship of scientific publications and recognition of the contribution of other parties in any Publication, including the then current authorship guidelines promulgated by the International Committee of Medical Journal Editors. Institution will disclose Pfizer support of the Study in all Publications.

7. INVENTIONS

7.1. Definitions.

7.1.1. "**Invention**" means any invention, idea, discovery, development, article of manufacture, improvement or innovation, whether or not patentable or registrable and whether or not recorded in any medium.

7.1.2. "**Product-Related Invention**" is any Invention which arises from or is supported by the Study Data or analysis thereof that: (i) encompasses treatment with, or the delivery, manufacture, form, formulation or use of, the Pfizer Product (including use in combination with other products or agents unless otherwise stated in this Agreement); or (ii) is or relates to a biomarker useful in selecting patients for treatment with the Pfizer Product.

7.2. Product-Related Inventions. Institution will grant and hereby grants to Pfizer a non-exclusive, sub-licensable, transferable, perpetual, irrevocable, worldwide, royalty-free, fully paid-up license for all purposes to each Product-Related Invention owned by it (including for avoidance of doubt any patent rights filed on such Invention). Such non-exclusive license will include the rights to: (i) sublicense to a Pfizer affiliate, contractor or collaborator working for the benefit of Pfizer or in connection with a product or service of Pfizer or a Pfizer affiliate, collaborator or contractor; and (ii) sublicense or assign to a successor-in-interest some or all rights in a Pfizer product to which the Product-Related Invention is relevant. Institution will grant and hereby grants to Pfizer the first right to negotiate an exclusive, sub-licensable, transferable, perpetual, irrevocable, worldwide license for all purposes, with full rights to sublicense and assign, to each Product-Related Invention owned in whole or in part by it, under terms to be negotiated in good faith between the parties. Institution will promptly inform Pfizer in writing upon generation of any Product-Related Invention.

7.3. Representation. If not already addressed by Institution policy or applicable employment laws, Institution represents that it has executed, or will execute, written agreements with

all Staff involved in the Study before they commence any Study-related activities that permits Institution to fully comply with the terms of this Agreement.

8. GLOBAL TRADE CONTROL LAWS

8.1. Global Trade Control Laws. The parties, affiliates and Staff involved in activities under this Agreement will perform the activities under this Agreement in full compliance with all Global Trade Control Laws set forth in Attachment B.

9. TERM AND TERMINATION

9.1. Term. This Agreement will commence on the Effective Date and will continue until the first anniversary thereof or until Study Completion, whichever is later, unless terminated earlier in accordance with its terms.

9.2. Termination.

9.2.1. *Termination Upon Study Completion*. This Agreement will terminate upon Study Completion and each party's receipt of all deliverables and payments owed.

9.2.2. *Termination by Institution*. Institution may terminate this Agreement upon 30 days prior written notice to Pfizer.

9.2.3. *Termination by Pfizer*. Pfizer may terminate this Agreement: (i) upon 60 days prior notice to Institution; (ii) upon 30 days prior written notice to Institution if (a) the Protocol is materially modified in a way unacceptable to Pfizer, (b) Study conduct is not completed within six months after the expected Study Completion date, (c) the Study does not start within six months of the Effective Date, or (d) the Study design or objectives are no longer scientifically relevant or if Pfizer ceases production, commercialization or development of the Pfizer Product; or (iii) immediately upon written notice to Institution if Principal Investigator becomes unavailable or withdraws from the Study and Pfizer and Institution are unable to agree upon a successor within 30 days after Pfizer is notified.

9.2.4. *Termination for Cause*. This Agreement may be terminated by either party upon written notice that specifically identifies a breach and gives the alleged breaching party 30 days to cure it. Notwithstanding the foregoing, Pfizer may terminate this Agreement immediately upon notice to Institution, with no cure period, if Institution violates Global Trade Control Laws or breaches Section 11.3.

9.3. Payment upon Early Termination. If the Study is terminated early for a reason other than for cause, Pfizer will pay for work already performed, in accordance with Attachment A, less payments already made for such work. Pfizer will also cover any non-cancelable expenses so long as they were properly incurred and prospectively approved by Pfizer and only to the extent, they cannot reasonably be mitigated. If the Study cannot be initiated because of disapproval by the IRB and through no fault of Institution, Pfizer will

reimburse Institution for IRB fees and any other expenses that were prospectively approved, in writing, by Pfizer.

9.4. Reconciliation. At Study Completion or termination of this Agreement, Institution will provide a detailed accounting of the costs and expenses for the Study compared to the budget and Pfizer payments. Institution agrees to refund any unused, undisbursed or misallocated funds. Upon request from Pfizer based on a good-faith belief that all or some portion of the ISR funding was not used in accordance with the terms of this Agreement, Institution will provide Pfizer access to all records related to the ISR funding to allow Pfizer to verify that the funding was used in accordance with the terms of this Agreement.

10. **INDEMNIFICATION**. The Study is not designed, sponsored or managed by Pfizer and Pfizer provides no indemnification of any type for Study conduct. However, Pfizer will indemnify, defend or cover costs of defense for, and hold harmless the Institution, its Staff, officers and directors (collectively, "**Indemnified Parties**") from any losses, including reasonable costs of defense, from any third-party demand or claim for damages ("**Claim**") that arises out of: (i) Pfizer's use of the Study Results or (ii) Pfizer's use of any Invention to which Pfizer receives a license under this Agreement; except to the extent that the Claim results from (a) any Indemnified Party's failure to conduct the Study in accordance with the Protocol, (b) negligence or willful misconduct by any Indemnified Party, or (c) a breach of any Applicable Law by any Indemnified Party.

11. REPRESENTATIONS

11.1. Representations of Both Parties. Each party represents that it: (i) has the requisite power and authority to enter into this Agreement and that this Agreement constitutes a legal and valid obligation binding upon such party, enforceable in accordance with its terms; and (ii) is not a party to any agreement that would prevent it from fulfilling its obligations under this Agreement.

11.2. Representations of Institution. Institution represents that it, its affiliates and Staff involved in the Study:

11.2.1. are licensed, registered or otherwise qualified and suitable (without restriction) under Applicable Law to act as a regulatory sponsor, Study site or investigator, as applicable;

11.2.2. are not debarred under subsections 306(a) or (b) of the US Federal Food, Drug, and Cosmetic Act or any other similar Applicable Law and will not use the services of any person debarred under Applicable Law in the Study;

11.2.3. are not the subject of any material past or pending governmental or regulatory investigation, warning or enforcement action related to its conduct of clinical research that has not been disclosed to Pfizer;

11.2.4. as applicable, are not excluded from, or prohibited from participating in, any national or federal health care program;

11.2.5. have the authority to share business contact information; and

11.2.6. will maintain true, accurate and complete reports, statements, books and other records related to the Study.

11.3. Anti-Bribery / Anti-Corruption Representations. Institution represents that:

11.3.1. the ISR Support will not cause Institution or its Staff to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;

11.3.2. it will not use any portion of the ISR Support to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, it has not accepted, and will not accept in the future, such a payment; and

11.3.3. Pfizer will be entitled to revoke the ISR Support if Pfizer learns that Institution or its Staff has used or intends to use any portion of the ISR Support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.

11.3.4. For the purpose of this Agreement, "**Government**" includes all levels and subdivisions of governments (i.e., local, regional, and national; administrative, legislative, and executive) and "**Government Official**" includes (i) any elected or appointed non-US Government official (e.g., a legislator or a member of a non-US Government ministry), (ii) any employee or individual acting for or on behalf of a non-US Government Official, non-US Government agency, or enterprise performing a function of, or owned or controlled by, a non-US Government (e.g., a healthcare professional employed by a non-US Government hospital), (iii) any non-US political party officer, candidate for non-US public office, or employee or individual acting for or on behalf of a non-US political party or candidate for public office, (iv) any employee or individual acting for or on behalf of a public international organization, and (v) any member of a royal family or member of a non-US military.

11.4. Amendment. During the term hereof and for three (3) years thereafter, Institution will notify Pfizer promptly if any of these representations require amendment during the term of this Agreement.

12. GENERAL PROVISIONS

12.1. No Third Party Beneficiaries. Nothing in this Agreement, whether express or implied, is

intended to confer upon any person, other than Pfizer and Institution, any rights or remedies under, or by reason of this Agreement. The benefits of this Agreement shall inure solely to the parties of this Agreement. The parties do not intend to create any third party beneficiary rights.

12.2. Assignment and Delegation. Institution may not assign any rights or delegate any duties under this Agreement without written permission from Pfizer. If Pfizer authorizes any delegation of duties, Institution remains responsible to Pfizer for the performance of those duties. Pfizer may assign and delegate its rights or obligations under this Agreement to a third party.

12.3. Entire Agreement. This Agreement, its Attachments and the Protocol represent the entire understanding, and supersede all previous agreements, between the parties relating to the Study. This Agreement may be amended only by a written instrument signed by both parties.

12.4. Survival. Sections **Errore. L'origine riferimento non è stata trovata.** – 7, 10 and 12 will survive Agreement termination, along with any other provision of this Agreement that, by its nature and intent, remains valid after termination.

12.5. Use of Names. Neither party will use the name or logos of the other or any of its Staff for promotional or advertising purposes without prior written consent. Institution is free to identify Pfizer as providing support for the Study in Publications or in publicly available reports of ongoing research studies. Pfizer is free to identify Institution, the Study, or the ISR Support in non-promotional listings or reports of Pfizer-supported ISR projects.

12.6. Conflict with Attachments or Protocol. If there is any conflict between this Agreement and any of its Attachments, the terms of this Agreement will control. If there is any conflict between the Agreement and the Protocol, the Agreement will control except with respect to medical, scientific or clinical matters relating to Study conduct, for which the Protocol will take precedence.

12.7. No Waiver. Any waiver, permit, consent, or approval of any kind or character on the part of either party of any breach or default under this Agreement, or any waiver on the part of either party of any provisions or conditions of this Agreement, must be in writing and will be effective only to the extent specifically set forth in such writing. All remedies available or afforded to either party pursuant to this Agreement or by law will be cumulative and not alternative.

[*signature page follows*]

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties.

Pfizer International LLC	**Fondazione IRCCS Policlinico Ca' Granda Ospedale Maggiore**
_____	_____
Authorized Representative	Authorized Representative
_____	_____
Amanda Stein	Dr. Fabio Blandini Scientific Director
_____	_____
Date	Date

Read and Acknowledged by:

_____	_____
Dr. Francesca Lazzaroni	Date

ATTACHMENT A
Payment Schedule

Investigator-Sponsored Research Study Tracking # 104003351
TOTAL ISR FUNDING AMOUNT: € 81,000.00
Funding includes any overhead allowance.

Milestone(s)	Description	Amount
Initial Payment	To be paid upon receipt by Pfizer of an executed copy of the Agreement, the Protocol, and documentation of IRB/IEC approval, exemption, or waiver. **Expected December 2026.**	**€ 81,000.00**

Payments: CyberGrants, Pfizer's online grant system, will automatically trigger payment upon completion of a milestone within the system by the Principal Investigator and acceptance thereof by the Pfizer Grant Administrator.

Inquiries: To inquire about a payment, e-mail GlobalMedicalGrants@pfizer.com and include Pfizer Tracking No. 104003351.

Pfizer will make payments of funding to:
Fondazione IRCCS Policlinico Ca' Granda Ospedale Maggiore
Via Francesco Sforza 35, Milan 20122, Italy

ATTACHMENT B

EXHIBIT Global Trade Control Laws

COMPLIANCE WITH LAWS

I. Mutual Representations and Covenants. Each Party represents, warrants, and covenants that:

Global Trade Controls

(a) It will comply with all Global Trade Control Laws, wherein "**Global Trade Control Laws**" means the U.S. Export Administration Regulations; the U.S. International Traffic in Arms Regulations; the U.S. economic sanctions rules and regulations implemented under statutory authority and/or the President's Executive Orders and administered by the U.S. Department of the Treasury Office of Foreign Assets Control; European Union (E.U.) Council Regulations on export controls, including Nos.428/2009, 267/2012; other E.U. Council sanctions regulations, as implemented in E.U. Member States; United Nations sanctions policies; all relevant regulations and legislative instruments made under any of the above; other relevant economic sanctions, export and import control laws, and other laws, regulations, legislation, orders and requirements imposed by a relevant governmental entity.

(b) Activities under this Agreement will not take place in, involve companies, organizations, or governmental entities from, nor involve individuals ordinarily resident in, a Restricted Market, wherein "**Restricted Market**" means the Crimean Peninsula, Cuba, the Donbass Region, Iran, North Korea, and Syria, or any other country or region sanctioned by the United States or European Union.

(c) It is not, and will not be, (i) a Restricted Party or (ii) owned or controlled by a Restricted Party, wherein "**Restricted Party**" means an individual or entity on the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals List and the Sectoral Sanctions Identifications List of the U.S. Treasury Department's Office of Foreign Assets Control; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List of the U.S. Department of Commerce; entities subject to restrictive measures and the Consolidated List of Persons, Groups and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign and Security Policy; the List of Excluded Individuals / Entities published by the U.S. Health and Human Services Office of Inspector General; any lists of prohibited or debarred parties established under the U.S. Federal Food Drug and Cosmetic Act; the list of parties suspended or debarred from contracting with the U.S. government; and similar lists of restricted parties maintained by the governmental entities of the countries that have jurisdiction over the activities conducted under this Agreement.

(d) It will not knowingly transfer any goods, software, technology, or services to the other party that are (i) controlled under the U.S. International Traffic in Arms Regulations or at a level other than EAR99 under the U.S. Export Administration Regulations; or (ii) specifically identified as an E.U. Dual Use Item or on an applicable export control list of another country.

(e) It will not engage or delegate any activities under this Agreement to a Restricted Party or to an individual that has previously been debarred or otherwise disqualified by the United States Food and Drug Administration or other regulatory or certification authority.

Equal Opportunity Employer

(a) **It will abide, as applicable, by the requirements of Executive Order 11246, 41 CFR 60-1.4(a); the Vietnam Era Veterans' Readjustment Assistance Act, 41 CFR 60-300.5(a); and Section 503 of the Rehabilitation Act of 1973, 41 CFR 60-741.5(a), and that these laws are incorporated herein by reference. These regulations prohibit discrimination against qualified individuals based on their status as protected veterans or individuals with disabilities, and prohibit discrimination against all individuals based on their race, color, religion, sex, sexual orientation, gender identity, or national origin. These regulations require that covered prime contractors and subcontractors take affirmative action to employ and advance in employment individuals without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability. In addition, as applicable, it will abide by the requirements of Executive Order 13496 (29 CFR Part 471, Appendix A to Subpart A), relating to the notice of employee rights under federal labor laws.**

Transparency

(a) It will provide the other Party or Parties with complete and accurate information about payments or other transfers of value reportable under those laws, regulations and industry codes that require the other Party or Parties to report payments or other transfers of value to certain healthcare professionals or teaching hospitals, including but not limited to section 6002 of the U.S. Affordable Care Act and the EFPIA Code on Disclosure of Transfers of Value (collectively, the "**Transparency Laws**"), and it agrees to (and will cause its agents, employees and contractors to) cooperate with collection and disclosure of information necessary for the other Party or Parties to meet its/their obligations under any Transparency Laws. For avoidance of doubt, each Party may disclose in any lawful manner the terms of this Agreement, the support or funding that it is providing under this Agreement, and any other related information, to the extent necessary for it to meet its obligations under the Transparency Laws.

Anti-Bribery and Anti-Corruption

(a) It acknowledges that most countries have anti-bribery and anti-corruption laws, including, but not limited to, the U.S. Foreign Corrupt Practices Act of 1977, which forbids directly or indirectly making, offering or promising of any payment or anything of value to government officials, or other persons, when the payment is intended to influence any act or decision to award or retain business and it represents and warrants it implements policies and procedures consistent with complying with such laws as applicable and that it will raise to the other Party any concerns related to a potential violation of anti-bribery and anti-corruption laws.

(b) It is and will remain licensed, registered, or qualified under local law, regulations, policies, and administrative requirements to do business and, to the extent required by applicable law, has obtained licenses or completed such registrations as may be necessary or required

by law to provide the goods and/or services described herein, and providing such goods and/or services is not inconsistent with any other obligation.

(c) It has not and will not in the future directly, or indirectly, offer or pay, or authorize the offer or payment, of any money or anything of value in an effort to influence any government official or any other person in order for the other Party to improperly obtain or retain business or to gain an improper business advantage, and, has not accepted, and will not accept in the future, such a payment.

(d) All information provided during any pre-contractual due diligence, if applicable, is complete, truthful and accurate.
In the case of the Party that is not Pfizer, it will: (i) provide truthful and complete documentation supporting, in reasonable detail, the work performed and expenses incurred, (ii) maintain true, accurate, and complete invoices, reports, statements, books, and other records, and as applicable (iii) secure pre-authorization in writing from Pfizer for any extraordinary expenditure.

Data Protection

(a) Pfizer may provide or other Party may gain access to certain information that can be used by itself or in combination with other available information to identify a specific individual ("**Personal Data**"). For sake of clarity, key-coded data relating to individual persons is considered to be Personal Data. Personal Data is hereby deemed Confidential Information of Pfizer.

(b) The receiving Party will immediately notify Pfizer upon becoming aware of any violation of applicable law relating to such Party's Processing of Personal Data. For the purposes of this Agreement, "**Processing**" will refer to any operation or set of operations which is performed upon Personal Data, whether or not by automatic means, including, without limitation, any collection, transfer, recording, organization, storage, adaptation, alteration, retrieval, consultation, use, disclosure, transmission, dissemination, combination, blocking, erasure or destruction thereof.

(c) The receiving Party and Pfizer acknowledge and agree that each is an independent Controller with respect to Personal Data. "**Controller**" means the entity that alone or jointly with other parties determines the purposes and means of the Processing of Personal Data.

(d) The receiving Party agrees to use reasonable and appropriate technical, organizational, and physical controls to protect all Personal Data under this Agreement, and to regularly test, assess and evaluate the effectiveness of the measures. Such controls will be appropriate to the nature of the information to prevent any breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure of, or access to Personal Data (collectively, "**Security Breach**").

(e) The receiving Party will notify Pfizer promptly, and in any event, within 24 hours of discovery of any Security Breach, and take immediate steps to consult with Pfizer in good faith regarding remediation to mitigate or rectify such Security Breach. The receiving Party will undertake remediation efforts at its sole expense, or reimburse Pfizer for Pfizer's reasonable costs and expenses incurred in connection with remediation efforts. Where Pfizer determines that any notifications are required by applicable law, receiving Party will

be responsible for all costs and expenses associated with the provision of such notification.

In addition to any method of notice described in this Agreement, notice of any Security Breach will also be reported to Pfizer's Global Security Operations Center: +1.212.733.7900 or +1.866.573.GSOC (4762) or gsocwatchroom@pfizer.com.

(f) To the extent Personal Data includes key-coded or otherwise anonymized data, the receiving Party will not attempt to re-identify the individual to whom the data relates and will implement protocols to minimize the risk of any identification of such individuals.

(g) Where applicable law requires the Parties to implement additional measures to effectuate international data transfers, the Parties will ensure the lawful export of Personal Data, the terms of which may be outlined in a separate agreement governing such transfer.

(h) The receiving Party will Process Personal Data only in accordance with Pfizer's instructions and applicable Pfizer policies and procedures provided to the receiving Party. The receiving Party will Process no more than the minimum amount of Personal Data necessary to perform its obligations under this Agreement.

II. Miscellaneous.

(a) During the term of this Agreement and for three years after final payment has been received, the Party receiving funding from the other Party will permit the paying Party's internal and external auditors to access any of its relevant books, documents, papers, and records involving transactions related to this Agreement.

(b) Pfizer provides the other Party with Personal Data, Pfizer will have the right to audit the other Party during such Party's normal business hours and on reasonable notice in order to monitor compliance with the terms the Data Protection provisions of this Exhibit.

(c) In the event that any of the representations in this Exhibit are inaccurate or if a Party is unable to comply with any of the covenants in this Exhibit, each Party will immediately inform the other Party or Parties in writing and suspend all affected activities, including but not limited to making any related payments, under this Agreement, until the notified Party agrees to move forward and end the suspension of the affected activities.

(d) Notwithstanding anything to the contrary herein, this Agreement, or any part thereof, may be terminated immediately by a Party for another Party's violation of the provisions above; and should a Party so terminate this Agreement the terminating Party will not be responsible for any related payments due, if any, even if activities have already occurred.